hypo-FLAME 3.0试验中肿瘤分割与治疗计划的自动化前瞻性质量保证
研究开发了一套自动化前瞻性质量保证系统,用于评估前列腺癌放疗中的肿瘤分割与治疗计划,并在多中心hypo-FLAME 3.0试验的研究组中实施。该系统处理了来自荷兰和比利时11个中心的134例患者数据,其中3例被建议重新分割、10例被建议重新计划。对外部机构的回复在12个工作小时内完成的比例分别为分割QA 77%和计划QA 81%。
要点
- 自动化QA系统可对肿瘤分割和计划进行前瞻性评估并生成集中审查报告。
- 在134例患者中,3例建议重新分割,10例建议重新计划。
- 分割和计划QA在12个工作小时内回复外部机构的比例分别为77%和81%。
核心结论
- 成功开发并实施了临床试验环境下的自动化前瞻性QA系统,覆盖hypo-FLAME 3.0 III期试验研究组全部患者。
研究设计与样本
- 开发自动化QA系统处理参与中心数据,应用肿瘤分割评估模型和计划评估模型并生成报告供集中审查。
- 肿瘤分割通过从MRI生成肿瘤概率图的模型评估,局灶 boost 质量通过基于解剖特征预测每个肿瘤可达到的近最小剂量的模型评估。
- 系统应用于2023年6月至2025年7月期间入组hypo-FLAME 3.0试验研究组的134例患者,来自荷兰和比利时11个中心。
主要发现
- 134例中3例被建议重新分割,10例被建议重新计划。
- 分割QA和计划QA分别在77%和81%的病例中在12个工作小时内回复外部机构。
临床怎么用
- 该系统可用于多中心临床试验中对前列腺癌局灶 boost 的肿瘤分割和治疗计划进行前瞻性自动化质量保证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Iso-toxic focal boosting in prostate cancer radiotherapy is associated with improved disease-free survival but faces challenges due to tumor segmentation variability and unconventional treatment planning. The aim of this study was to develop an automated system of prospective quality assurance (QA) on tumor segmentation and treatment planning in a clinical trial setting and to implement it in the study arm of the multi-center hypo-FLAME 3.0 trial (NCT05705921) on iso-toxic focal boosting. MATERIALS AND METHODS: We developed an automated QA system to process data from participating centers, apply tumor segmentation evaluation models and plan evaluation models and generate reports for centralized review. Tumor segmentation was evaluated by a model generating tumor probability maps from MRI scans. Focal boost quality was evaluated with a model predicting achievable near-minimum dose for each tumor based on anatomical features. RESULTS: The QA system was applied to 134 patients who participated in the study arm of the hypo-FLAME 3.0 trial between June 2023 and July 2025. They were recruited from 11 centers in the Netherlands and Belgium. Three and 10 out of 134 cases were recommended for resegmentation and replanning, respectively. We responded to external institutes within 12 business hours in 77% and 81% of the cases for the segmentation and the planning QA, respectively. CONCLUSION: We developed an automated system of prospective QA in a clinical trial setting and implemented it for all patients in the study arm of the phase III hypo-FLAME 3.0 trial.
引用
- Surewaard J, Bosschaert R, Beemster H, et al. Automated prospective quality assurance of tumor segmentation and treatment planning in the hypo-FLAME 3.0 trial. Radiother Oncol. 2026. PMID: 42208742. doi:10.1016/j.radonc.2026.111608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。